Can a weekly weight-loss shot really cut back on heavy drinking?
Yes. In a 26-week randomized trial of 108 adults with alcohol use disorder and obesity, once-weekly semaglutide reduced heavy drinking days by 41.1 percentage points, compared with a 26.4 point drop on placebo. That extra 13.7 point difference was statistically significant (p=0.0015), and the drug also lowered cravings and improved liver health.
Semaglutide is the same medicine sold as Ozempic and Wegovy. It belongs to a class of drugs called GLP-1 receptor agonists, which were designed to treat type 2 diabetes and obesity. For years, patients and doctors have noticed something unexpected: people on these drugs often report that they no longer enjoy alcohol the way they used to. This trial is one of the first high-quality tests of whether that effect is real and whether it can actually help people with alcohol use disorder.
What the trial found
Researchers enrolled 108 adults who had moderate to severe alcohol use disorder along with obesity. Everyone in the study received standard cognitive behavioural therapy. Half were randomly assigned to weekly injections of semaglutide 2.4 mg, and half got matching placebo injections. Neither the patients nor the doctors knew who was getting the real drug.
After 26 weeks, both groups were drinking less, which is common when people enroll in any treatment program. But the semaglutide group cut their heavy drinking days much further. They also drank less overall, reported weaker cravings, and showed better liver biomarkers, the blood tests that signal whether the liver is recovering from alcohol stress. The number needed to treat was 4.3. That means roughly one out of every four or five people treated with semaglutide had a meaningful response that they would not have had on placebo. For comparison, the medicines currently approved for alcohol use disorder have a number needed to treat of seven or higher, so semaglutide looks notably more effective in this specific population.
Dr. Kumar’s Take
I find this result genuinely exciting, but I want to be careful about how I frame it. Alcohol use disorder is one of the most undertreated conditions in medicine. The few approved drugs we have, like naltrexone and acamprosate, help some people but are rarely prescribed and often modestly effective. If a medicine that millions of people are already taking for weight loss also blunts the urge to drink, that could quietly become one of the most important public health stories of the decade. That said, this is a single trial of 108 people. We do not yet know how durable the effect is after six months, how it works in people who are not obese, or whether the benefit lasts once the injections stop. I would not call semaglutide an alcohol use disorder treatment today. I would call it a very promising signal that deserves bigger and longer trials right away.
How might semaglutide change drinking behavior?
GLP-1 drugs act on receptors in the brain’s reward circuits, the same circuits that respond to food, alcohol, and other addictive substances. Animal studies have shown for years that activating these receptors reduces alcohol intake. The leading theory is that semaglutide turns down the dopamine response that makes alcohol feel rewarding, while also reducing the appetite and craving signals that drive people to drink. Patients in this trial described alcohol as less appealing rather than forbidden, which is a meaningfully different experience from the willpower-heavy approach of traditional treatment.
Important limitations
The trial only lasted 26 weeks, so we do not know what happens long term. Everyone in the study also had obesity, so the results may not apply to people with alcohol use disorder who are at a normal weight. Side effects of semaglutide, including nausea, vomiting, and in rare cases pancreatitis, are real and can be significant. And because this was a single trial run at a limited number of sites, the findings need to be replicated before guidelines change.
Practical Takeaways
- If you or someone you love struggles with heavy drinking and also has obesity or type 2 diabetes, ask your doctor whether semaglutide is appropriate, since it may offer benefits on both fronts.
- Do not stop existing alcohol use disorder treatments to try semaglutide on your own, because this drug is not yet approved for alcohol use disorder and should be used under medical supervision.
- Combine any medication with behavioural support, since the trial paired semaglutide with cognitive behavioural therapy and did not test the drug alone.
- Pay attention to side effects, especially nausea, dehydration, and gallbladder symptoms, and report them to your prescriber early rather than waiting.
Related Studies and Research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- A randomized controlled trial of mindfulness-based cognitive therapy for major depressive disorder in undergraduate students
- Open water swimming as a treatment for major depressive disorder
- Normobaric oxygen treatment for mild-to-moderate depression: RCT
FAQs
Is semaglutide approved to treat alcohol use disorder?
No. Semaglutide is currently approved for type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). Using it for alcohol use disorder would be considered off-label, meaning a doctor can legally prescribe it but it has not been formally cleared for that purpose by regulators. The results from this trial are a strong early signal, but most experts will want to see larger and longer studies before recommending semaglutide as a standard treatment for drinking problems.
Does semaglutide work for people who drink heavily but are not obese?
This trial cannot answer that question, because every participant had obesity. There are good biological reasons to think the brain reward effects would carry over to people at a normal weight, but the side effect profile may look different in patients who do not need to lose weight. Rapid weight loss in someone who is already lean could cause muscle loss and nutritional issues. Ongoing trials are testing semaglutide in alcohol use disorder without an obesity requirement, and those results will be important.
How does semaglutide compare with naltrexone and acamprosate?
Naltrexone and acamprosate are the two most commonly used medicines for alcohol use disorder in the United States, and both have a number needed to treat of around seven or higher. That means you need to treat about seven people to see one meaningful responder. In this trial, semaglutide’s number needed to treat was 4.3, which suggests a stronger effect, although it is a single study and the comparison is indirect. Semaglutide also works through a completely different pathway, so it may help people who did not respond to the older drugs.
Bottom Line
In a rigorous randomized trial, weekly semaglutide cut heavy drinking days far more than placebo in adults with alcohol use disorder and obesity, with a number needed to treat that beats currently approved medicines. The findings are early and need to be confirmed in larger and longer studies, but they suggest that a drug already in millions of medicine cabinets may also be one of the most promising tools we have seen for one of medicine’s hardest problems.
